Warfarin for stroke prevention in atrial fibrillation: Time to switch?

International Journal of Clinical Practice

Volumn 67, Issue 7, 2013, Pages 603-605

  Ahmad, Y ^a   Lip, G Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; KETOCONAZOLE; RIVAROXABAN; THROMBIN INHIBITOR; VERAPAMIL; WARFARIN;

CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG INTERACTIONS; DRUG SUBSTITUTION; HUMANS; INTERNATIONAL NORMALIZED RATIO; PRACTICE GUIDELINES AS TOPIC; STROKE; VITAMIN K; WARFARIN;

EID: 84879122616     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12157     Document Type: Review

References (11)

1. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
2. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006. Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-98.
3. Skanes AC, Healey JS, Cairns JA, et al.; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125-36
4. Authors/Task Force Members, Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47
5. Ahmad Y, Lip GY,. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012; 98: 1404-6.
6. Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F,. The management of oral anticoagulant therapy: the patient's point of view. Thromb Haemost 2000; 83: 49-53.
7. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP,. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-77.
8. Wallentin L, Yusuf S, Ezekowitz MD, et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83.
9. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A,. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-47.
10. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S,. Management consensus guidancefor the use of rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-86.
11. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY,. The value of the CHA2DS2-VAScscore for refining stroke risk stratification in patients with atrialfibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-9.